A Single Dose Study to Evaluate the Pharmacokinetics of Acoramidis Modified Release Formulations in Healthy Subjects

Sponsor
Eidos Therapeutics, a BridgeBio company
Study ID
NCT04769479
Phase
PHASE1
Status
Completed

Conditions

  • Amyloidosis

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

Study Details

This is a single centre, open-label, 5-period study in healthy male and non-pregnant and non-lactating healthy female subjects.

Key Dates

Start date
Mar 28, 2021
Status verified
Mar 2022
Primary completion
Aug 4, 2021
Completion
Sep 3, 2021

Study Design

Enrollment
14 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: acoramidis

Primary Outcome Measure

Pharmacokinetic Assessments: Cmax [ Time Frame: 72 hours ]

Related Studies